Utility of speech-based digital biomarkers for evaluating disease progression in clinical trials of Alzheimer's disease

William Simpson, PhD 1,2, Liam D. Kaufman, MSc 2, Mike Detke, MD PhD 3, Casey Lynch, MSc 3, Adam Butler BA 2, Steve Dominy, MD 3

(1) Department of Psychiatry and Behavioural Neuroscience, McMaster University, Hamilton, ON, Canada, (2) Winterlight Labs, Toronto, ON, Canada, (3) Cortexyme Inc, South San Francisco, CA, USA.

Background
Recent clinical trials in Alzheimer's disease have been overwhelmingly negative, spurring development of novel biomarkers which might capture changes in cognitive function with greater precision. Computational analysis of speech and language represent one such group of biomarkers (1,2). The objective of this study was to examine the utility of a speech-based digital biomarker for tracking disease progression and treatment response to investigational treatment COR388 in a group of patients with Alzheimer’s disease.

Methods
- This study was a small, double-blind placebo-controlled Phase 1b trial (NCT03418688) of COR388 with a cohort of nine individuals with Alzheimer’s disease.
- Participants were randomized to receive COR388 (6) or placebo (3) in a 2:1 fashion, BID for 28 days.
- A tablet-based speech and language assessment was administered at Days 1, 15 and 28. Participants were asked to complete 2 picture description tasks and verbal responses were analyzed.
- Using natural language processing techniques, audio samples and transcripts were analyzed to generate 3 experimental composite metrics, chosen for their previous association to AD: syntactic complexity, information units and word finding difficulty (WFD).

Results
- Previous analysis of single outcomes showed significant improvement in the quality of picture descriptions for COR388 patients relative to placebo (increase in unique object content units, p=0.016 and prepositions, p=0.0011) (3).
- Positive trends, but no significant differences in MMSE scores were also observed.
- For experimental composite markers, mean baseline to endpoint comparisons showed trend level improvements in information units, syntactic complexity and word finding difficulty in those treated with COR388.
- No significant within-subject differences were observed for placebo on any of 3 metrics.

Figure 1: Baseline to endpoint change scores for MMSE, prepositions, information units, syntactic complexity and word finding difficulty

Figure 2: Mean change in prepositions and word finding difficulty

Table 1: Between group comparisons for all metrics

<table>
<thead>
<tr>
<th>Metric</th>
<th>Mean Change (Baseline-Day 28)</th>
<th>Within group p</th>
<th>Between group p</th>
</tr>
</thead>
<tbody>
<tr>
<td>MMSE</td>
<td>1.67 ± 0.66</td>
<td>0.052</td>
<td>0.576</td>
</tr>
<tr>
<td>Information Units</td>
<td>0.093 ± 0.047</td>
<td>0.002</td>
<td>0.132</td>
</tr>
<tr>
<td>Syntactic Complexity</td>
<td>0.114 ± 0.126</td>
<td>0.094</td>
<td>0.245</td>
</tr>
<tr>
<td>Word Finding Difficulty</td>
<td>-0.345 ± 0.517</td>
<td>0.570</td>
<td>0.245</td>
</tr>
</tbody>
</table>

(Bold) exceeds Bonferroni threshold p

Conclusions
- In this preliminary trial, patients treated with COR388 showed signs of significant improvement relative to placebo using a speech-based, digital biomarker.
- No significant changes in MMSE were observed suggesting that composite metrics derived from speech may represent sensitive tools for tracking changes in cognition in small trials.
- The study highlights the potential therapeutic benefit of COR388, though additional studies of sufficient power are needed.

References

Presented at Alzheimer's Association International Conference (AAIC) 2019, Los Angeles, CA, USA. July 14-18, 2019